A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
Thromb Res
; 133(2): 190-5, 2014 Feb.
Article
en En
| MEDLINE
| ID: mdl-24368019
Palabras clave
ADP; Biomarkers; CD40 ligand; CD40L; EDTA; GPIIbIIIa; P2Y(12) receptor antagonist; PD; PK; Platelets; Prasugrel; RBCs; SCD; SD; Sickle cell disease; TF; TXB(2); VOC; adenosine diphosphate; ethylenediaminetetraacetic acid; glycoprotein IIb-IIIa; pharmacodynamics; pharmacokinetics; red blood cells; sickle cell disease; standard deviation; thromboxane B(2); tissue factor; vaso-occlusive crisis
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Piperazinas
/
Tiofenos
/
Coagulación Sanguínea
/
Plaquetas
/
Activación Plaquetaria
/
Antagonistas del Receptor Purinérgico P2Y
/
Anemia de Células Falciformes
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Thromb Res
Año:
2014
Tipo del documento:
Article
Pais de publicación:
Estados Unidos